Abstract:The 1921 discovery of insulin was a Big Bang from which a vast and expanding universe of research into insulin action and resistance has issued. In the intervening century, some discoveries have matured, coalescing into solid and fertile ground for clinical application; others remain incompletely investigated and scientifically controversial. Here, we attempt to synthesize this work to guide further mechanistic investigation and to inform the development of novel therapies for type 2 diabetes (T2D). The rational development of such therapies necessitates detailed knowledge of one of the key pathophysiological processes involved in T2D: insulin resistance. Understanding insulin resistance, in turn, requires knowledge of normal insulin action. In this review, both the physiology of insulin action and the pathophysiology of insulin resistance are described, focusing on three key insulin target tissues: skeletal muscle, liver, and white adipose tissue. We aim to develop an integrated physiological perspective, placing the intricate signaling effectors that carry out the cell-autonomous response to insulin in the context of the tissue-specific functions that generate the coordinated organismal response. First, in section II, the effectors and effects of direct, cell-autonomous insulin action in muscle, liver, and white adipose tissue are reviewed, beginning at the insulin receptor and working downstream. Section III considers the critical and underappreciated role of tissue crosstalk in whole body insulin action, especially the essential interaction between adipose lipolysis and hepatic gluconeogenesis. The pathophysiology of insulin resistance is then described in section IV. Special attention is given to which signaling pathways and functions become insulin resistant in the setting of chronic overnutrition, and an alternative explanation for the phenomenon of ‟selective hepatic insulin resistanceˮ is presented. Sections V, VI, and VII critically examine the evidence for and against several putative mediators of insulin resistance. Section V reviews work linking the bioactive lipids diacylglycerol, ceramide, and acylcarnitine to insulin resistance; section VI considers the impact of nutrient stresses in the endoplasmic reticulum and mitochondria on insulin resistance; and section VII discusses non-cell autonomous factors proposed to induce insulin resistance, including inflammatory mediators, branched-chain amino acids, adipokines, and hepatokines. Finally, in section VIII, we propose an integrated model of insulin resistance that links these mediators to final common pathways of metabolite-driven gluconeogenesis and ectopic lipid accumulation.

Insulin signaling to hepatic lipid metabolism in health and disease

The Interactions of Insulin and Vitamin A Signaling Systems for the Regulation of Hepatic Glucose and Lipid Metabolism

Physiological and pathophysiological actions of insulin in the liver

Insulin signalling and the regulation of glucose and lipid metabolism

Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders

Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation

Mechanisms of Insulin Action and Insulin Resistance

Recent Advances in Our Understanding of Insulin Action and Insulin Resistance

Insulin Resistance, Obesity, and Lipotoxicity

Hepatic CREBZF Couples Insulin to Lipogenesis by Inhibiting Insig activity and Contributes to Hepatic Steatosis in Diet-Induced Insulin-Resistant Mice.

The aetiology and molecular landscape of insulin resistance

The crucial role and mechanism of insulin resistance in metabolic disease

Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies

Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease

Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease.

Bile Acids and Insulin Resistance: Implications for Treating Nonalcoholic Fatty Liver Disease

Hepatic Insulin/Snail1 Axis Protects Against Liver Steatosis and Insulin Resistance Through Epigenetically Suppressing Lipogenesis

Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis

The liver as an endocrine organ - linking NAFLD and insulin resistance.

Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease.

Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids